Publications by authors named "Jonathan Lochner"
Article Synopsis
- Clinical trials on CAR T-cell therapy for relapsed/refractory multiple myeloma usually exclude patients with AL amyloidosis, leading to a lack of data on its effectiveness for this group.
- A study reviewed eight patients with both RRMM and AL amyloidosis who underwent standard CAR T-cell therapy, revealing that 75% experienced cytokine release syndrome and low-grade cytopenias were common.
- The therapy resulted in rapid and significant responses, with a median time to best response of 43 days and a 62.5% rate of achieving a very good partial response or better, indicating that CAR T-cell therapy is feasible and effective for these patients.
Methotrexate (MTX) doses on days +1, +3, +6, and +11 after match unrelated donor allogeneic stem cell transplant (MUD HSCT) is a common graft-versus-host disease (GVHD) prophylaxis regimen. However, the overlapping toxicity of MTX with conditioning chemotherapy sometimes warrants the omission of the fourth dose of MTX. Prior single-institution studies showed conflicting results comparing the outcomes of patients who received three versus four doses of MTX, but to our knowledge, the effect of concomitant antithymocyte globulin (ATG) has not been reported.
View Article and Find Full Text PDFIntroduction: Rupture of the gestational membranes often precedes major pregnancy complications, including preterm labor and preterm birth. One major cause of inflammation in the gestational membranes, chorioamnionitis (CAM) is often a result of bacterial infection. The commensal bacterium , or Group B (GBS) is a leading infectious cause of CAM.
View Article and Find Full Text PDFArticle Synopsis
- Teclistamab, a bispecific antibody targeting B cell maturation antigen, shows promising efficacy in treating relapsed/refractory multiple myeloma (RRMM) based on the real-world outcomes of 106 patients, most of whom would have been ineligible for clinical trials.
- The overall response rate (ORR) was 66%, with a complete or better response rate of 29%, and the median progression-free survival (PFS) was 5.4 months.
- Adverse events included cytokine release syndrome in 64% of patients and infections in 31%, with a focus on specific patient factors like age and baseline health status affecting outcomes.
Preterm birth affects nearly 10% of all pregnancies in the United States, with 40% of those due, in part, to infections. (Group B , GBS) is one of the most common perinatal pathogens responsible for these infections. Current therapeutic techniques aimed to ameliorate invasive GBS infections are less than desirable and can result in complications in both the neonate and the mother.
View Article and Find Full Text PDF